Cytokine and Chemokine Profile Changes in Patients with Neovascular Age-Related Macular Degeneration After Intravitreal Ranibizumab Injection for Choroidal Neovascularization

References

• KawasakiR, YasudaM, SongSJ, et al. The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology. 2010;117(5):921–927. doi:10.1016/j.ophtha.2009.10.00720110127
   PubMed Web of Science ®Google Scholar
• WongTY, ChakravarthyU, KleinR, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2008;115(1):116–126. doi:10.1016/j.ophtha.2007.03.00817675159
   PubMed Web of Science ®Google Scholar
• HandaJT, Bowes RickmanC, DickAD, et al. A systems biology approach towards understanding and treating non-neovascular age-related macular degeneration. Nat Commun. 2019;10(1):3347. doi:10.1038/s41467-019-11262-131350409
   PubMed Web of Science ®Google Scholar
• FerraraN, DamicoL, ShamsN, LowmanH, KimR. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26(8):859–870. doi:10.1097/01.iae.0000242842.14624.e717031284
   PubMed Web of Science ®Google Scholar
• RosenfeldPJ, BrownDM, HeierJS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi:10.1056/NEJMoa05448117021318
   PubMed Web of Science ®Google Scholar
• HeierJS, AntoszykAN, PavanPR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a Phase I/II multicenter, controlled, multidose study. Ophthalmology. 2006;113(4):633–642. doi:10.1016/j.ophtha.2005.10.05216483659
   PubMed Web of Science ®Google Scholar
• GaleRP, PearceI, EterN, et al. Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study. Br J Ophthalmol. 2020;104(4):493–499. doi:10.1136/bjophthalmol-2019-31425131383649
   PubMed Web of Science ®Google Scholar
• WadaI, OshimaY, ShioseS, et al. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients. Graefe’s Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie. 2019;257(7):1411–1418. German. doi:10.1007/s00417-019-04361-8
   Web of Science ®Google Scholar
• AgawaT, UsuiY, WakabayashiY, et al. Profile of intraocular immune mediators in patients with age-related macular degeneration and the effect of intravitreal bevacizumab injection. Retina. 2014;34(9):1811–1818. doi:10.1097/IAE.000000000000015724801651
   PubMed Web of Science ®Google Scholar
• KauppinenA, PaternoJJ, BlasiakJ, SalminenA, KaarnirantaK. Inflammation and its role in age-related macular degeneration. Cell Mol Life Sci. 2016;73(9):1765–1786. doi:10.1007/s00018-016-2147-826852158
   PubMed Web of Science ®Google Scholar
• JabsDA, Van NattaML, TrangG, et al. Association of age-related macular degeneration with mortality in patients with acquired immunodeficiency syndrome; role of systemic inflammation. Am J Ophthalmol. 2019;199:230–237. doi:10.1016/j.ajo.2018.12.00230552890
   PubMed Web of Science ®Google Scholar
• ScottiF, MilaniP, SetaccioliM, et al. Increased soluble urokinase plasminogen activator receptor (suPAR) levels in neovascular age-related macular degeneration: a role for inflammation in the pathogenesis of the disease? Graefe’s Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie. 2019;257(5):899–903. German. doi:10.1007/s00417-018-04230-w
   Web of Science ®Google Scholar
• BikfalviA, HanZC. Angiogenic factors are hematopoietic growth factors and vice versa. Leukemia. 1994;8(3):523–529.7510358
   PubMed Web of Science ®Google Scholar
• AlloucheM, BikfalviA. The role of fibroblast growth factor-2 (FGF-2) in hematopoiesis. Prog Growth Factor Res. 1995;6(1):35–48. doi:10.1016/0955-2235(95)00041-08714368
   PubMedGoogle Scholar
• LoganA, FrautschySA, BairdA. Basic fibroblast growth factor and central nervous system injury. Ann N Y Acad Sci. 1991;638:474–476. doi:10.1111/j.1749-6632.1991.tb49073.x1785823
   PubMed Web of Science ®Google Scholar
• BikfalviA, KleinS, PintucciG, RifkinDB. Biological roles of fibroblast growth factor-2. Endocr Rev. 1997;18(1):26–45. doi:10.1210/edrv.18.1.02929034785
   PubMed Web of Science ®Google Scholar
• LinN, FanW, SheedloHJ, TurnerJE. Basic fibroblast growth factor treatment delays age-related photoreceptor degeneration in Fischer 344 rats. Exp Eye Res. 1997;64(2):239–248. doi:10.1006/exer.1996.02089176058
   PubMed Web of Science ®Google Scholar
• DesireL, CourtoisY, JeannyJC. Suppression of fibroblast growth factors 1 and 2 by antisense oligonucleotides in embryonic chick retinal cells in vitro inhibits neuronal differentiation and survival. Exp Cell Res. 1998;241(1):210–221. doi:10.1006/excr.1998.40489633530
   PubMed Web of Science ®Google Scholar
• GuoS, YinH, ZhengM, et al. Cytokine profiling reveals increased serum inflammatory cytokines in idiopathic choroidal neovascularization. BMC Ophthalmol. 2019;19(1):94. doi:10.1186/s12886-019-1101-631014258
   PubMed Web of Science ®Google Scholar
• YinH, FangX, MaJ, et al. Idiopathic choroidal neovascularization: intraocular inflammatory cytokines and the effect of intravitreal ranibizumab treatment. Sci Rep. 2016;6:31880. doi:10.1038/srep3188027558944
   PubMed Web of Science ®Google Scholar
• DeshauerC, MorganAM, RyanEO, HandelTM, PrestegardJH, WangX. Interactions of the chemokine CCL5/RANTES with medium-sized chondroitin sulfate ligands. Structure. 2015;23(6):1066–1077. doi:10.1016/j.str.2015.03.02425982530
   PubMed Web of Science ®Google Scholar
• GriffithJW, SokolCL, LusterAD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol. 2014;32:659–702. doi:10.1146/annurev-immunol-032713-12014524655300
   PubMed Web of Science ®Google Scholar
• BaltusT, von HundelshausenP, MauseSF, BuhreW, RossaintR, WeberC. Differential and additive effects of platelet-derived chemokines on monocyte arrest on inflamed endothelium under flow conditions. J Leukoc Biol. 2005;78(2):435–441. doi:10.1189/jlb.030514115899984
   PubMed Web of Science ®Google Scholar
• OynebratenI, BaroisN, BergelandT, KuchlerAM, BakkeO, HaraldsenG. Oligomerized, filamentous surface presentation of RANTES/CCL5 on vascular endothelial cells. Sci Rep. 2015;5:9261. doi:10.1038/srep0926125791723
   PubMed Web of Science ®Google Scholar
• DuncanDS, WeinerRL, WeitlaufC, et al. Ccl5 mediates proper wiring of feedforward and lateral inhibition pathways in the inner retina. Front Neurosci. 2018;12:702. doi:10.3389/fnins.2018.0070230369865
   PubMed Web of Science ®Google Scholar
• AdlerMW, GellerEB, ChenX, RogersTJ. Viewing chemokines as a third major system of communication in the brain. AAPS J. 2006;7(4):E865–70. doi:10.1208/aapsj07048416594639
   PubMed Web of Science ®Google Scholar
• ShirakiY, ShojiJ, InadaN. Clinical usefulness of monitoring expression levels of CCL24 (Eotaxin-2) mRNA on the ocular surface in patients with vernal keratoconjunctivitis and atopic keratoconjunctivitis. J Ophthalmol. 2016;2016:3573142. doi:10.1155/2016/357314227721987
   PubMed Web of Science ®Google Scholar
• TakedaA, BaffiJZ, KleinmanME, et al. CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature. 2009;460(7252):225–230. doi:10.1038/nature0815119525930
   PubMed Web of Science ®Google Scholar
• SakamotoS, TakahashiH, TanX, et al. Changes in multiple cytokine concentrations in the aqueous humour of neovascular age-related macular degeneration after 2 months of ranibizumab therapy. Br J Ophthalmol. 2018;102(4):448–454. doi:10.1136/bjophthalmol-2017-31028428765149
   PubMed Web of Science ®Google Scholar
• McCollBK, StackerSA, AchenMG. Molecular regulation of the VEGF family – inducers of angiogenesis and lymphangiogenesis. APMIS. 2004;112(7–8):463–480. doi:10.1111/j.1600-0463.2004.apm11207-0807.x15563310
   PubMed Web of Science ®Google Scholar
• AdamsRH, AlitaloK. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol. 2007;8(6):464–478. doi:10.1038/nrm218317522591
   PubMed Web of Science ®Google Scholar
• GuyotM, PagesG. VEGF splicing and the role of VEGF splice variants: from physiological-pathological conditions to specific pre-mRNA splicing. Methods Mol Biol. 2015;1332:3–23. doi:10.1007/978-1-4939-2917-7_126285742
   PubMedGoogle Scholar
• TongJP, ChanWM, LiuDT, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol. 2006;141(3):456–462. doi:10.1016/j.ajo.2005.10.01216490490
   PubMed Web of Science ®Google Scholar
• RohMI, LimSJ, AhnJM, LimJB, KwonOW. Concentration of cytokines in age-related macular degeneration after consecutive intravitreal bevacizumab injection. Graefe’s Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie. 2010;248(5):635–640. German. doi:10.1007/s00417-009-1254-8
   Web of Science ®Google Scholar